Previous 10 | Next 10 |
Palm Beach, FL – December 3, 2020 – Acute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a median age at diagnosis of 66 years but also includes about 15% of children from birth to 19 ye...
Gainers: Catabasis Pharmaceuticals (CATB) +44%, iBio (IBIO) +21%, Cellectar Biosciences (CLRB) +21%, Intec Pharma (NTEC) +18%, Sio Gene Therapies (SIOX) +18%.Losers: Ovid Therapeutics (OVID) -55%, Auris Medical (EARS) -35%, iRhythm Techno...
iBio (IBIO) jumps 12% in premarket after entering into its first Statement of Work under a Master Services Agreement with Belgium-based ATB Therapeutics to produce its bio-engineered antibody-toxin fusion proteins using iBio’s FastPharming System.The...
3 Penny Stocks to Watch Making Big Waves This Month In the past thirty days, we have seen a great deal of positive momentum with many penny stocks . This is not to say that all penny stocks have climbed, but rather a select few. During that time, we have seen specific areas of t...
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first...
iBio ([[IBIO]] +0.7%) announced that its has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell shares of the Company’s common stock, par value $0.001 per share, from time to time, through an “at the market offering” pr...
FinancialBuzz.com News Commentary New York, NY (11/25/2020) – As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data. Dr. Anthony Fauci, the National Institute of Allergy and Infectious Disea...
The USPTO has issued iBio (IBIO), the U.S. Patent No. 10,844,392, entitled “Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,” which, amongst other claims, covers a novel expression cassette that enhances the yield of endostatin fr...
BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- iBio , Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S. P...
Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...